Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-13
2006-06-13
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
07060674
ABSTRACT:
Disclosed herein is a composition and a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.
REFERENCES:
patent: 4705777 (1987-11-01), Lehrer et al.
patent: 5200182 (1993-04-01), Kiczka
patent: 5849490 (1998-12-01), Schonwetter et al.
patent: 5942217 (1999-08-01), Woo et al.
patent: 6335318 (2002-01-01), Selsted et al.
Aebi, C., et al. (1996) Expression of the CopB Outer Membrane Protein byMoraxella catarrhalisIs Regulated by Iron and Affects Iron Acquisition from Transferrin and Lactoferrin. Infect. Immum. 64(6):2024-2030.
Arnold, R. R., et al. (1982) Bactericidal Activity of Human Lactoferrin: Differentiation from the Stasis of Iron Deprivation. Infect. Immun. 35(3):792-799.
Arnold, R. R., et al. (1977) A Bactericidal Effect for Human Lactoferrin. Science. 197:263-265.
Bals, R., et al. (1998) Human β-Defensin 2 is a Salt-Sensitive Peptide Antibiotic Expressed in Human Lung. J. Clin. Invest. 102:874-880.
Bals, R., et al. (1998) Mouse β-Defensin 1 Is a Salt-Sensitive Antimicrobial Peptide Present in Epithelia of the Lung and Urogenital Tract. Infect. Immun. 66(3):1225-1232.
Bernstein, J. M. & Ogra, P. L. (1980) Mucosal immune system: implications in otitis media with effusion. Ann. Otol. Rhinol. Laryngol. Suppl. 89(Suppl 68):326-332.
Block, S. L. (1997) Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr. Infect. Dis. J. 16:449-456.
Bluestone, C. D. and Klein, J. O. (1995) Otitis Media in Infants and Children, 2nd Edition, W.B. Saunders Company, Philadelphia.
Boe, R., et al. (1999) Human β-defensin-1 mRNA Is Transcribed in Tympanic Membrane and Adjacent Auditory Canal Epithelium. Infect. Immun. 67(9):4843-4846.
Bonnah, R. A., et al. (1998) Biochemical and immunological properties of lactoferrin binding proteins fromMoraxella(Branhamella)catarrhalis. Microb. Pathog. 24:89-100.
Bowes; D. & Corrin, B. (1977) Ultrastructural immunocytochemical localisation of lysozyme in human bronchial glands. Thorax. 32:163-170.
Brook, I. (1994) Otitis Media: Microbiology and Management. J. Otolaryngol. 23(4):269-275.
Campagnari, A. A., et al. (1994) Growth ofMoraxella catarrhaliswith Human Transferrin and Lactoferrin: Expression of Iron-Repressible Proteins Without Siderophore Production. Infect. Immun. 62(11):4909-14.
Chartrand, S. A. & Pong, A. (1998) Acute Otitis Media in the 1990s: The Impact of Antibiotic Resistance. Pediatr. Ann. 27(2):86-95.
Ellison, R. T., III (1994) The effects of lactoferrin on gram-negative bacteria. Adv. Exp. Med. Biol. 357:71-90.
Ganz, T. & Lehrer, R. I. (1995) Defensins. Pharmacol. Ther. 66:191-205.
Ganz, T. & Lehrer, R. I. (1998) Antimicrobial peptides of vertebrates. Curr. Opin. Immunol. 10:41-44.
Garcia, J. R., et al. (2001) Human β-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 15:1819-21.
Goldoni, P., et al. (2000) Metal complexes of lactoferrin and their effect on the intracellular multiplication ofLegionella pneumophila. Biometals 13:15-22.
Hanamure, Y. & Lim, D. J. (1986) Normal Distribution of Lysozyme- and Lactoferrin-secreting Cells in the Chinchilla Tubotympanum. Am. J. Otolaryngol. 4:410-425.
Harder, J., et al. (2001) Isolation and Characterization of Human β-Defensin-3, a Novel Human Inducible Peptide Antibiotic. J. Biol. Chem. 276(8):5707-1713.
Hiratsuka, T., et al. (1998) Identification of Human β-Defensin-2 in Respiratory Tract and Plasma and Its Increase in Bacterial Pneumonia. Biochem. Biophys. Res. Commun. 249:943-947.
Hoppe, H. L. & Johnson, C. E. (1998) Otitis media: Focus on antimicrobial resistance and new treatment options. Am. J. Health Syst. Pharm. 55(18):1881-1897.
Jia, H. P., et al. (2001) Discovery of new human β-defensins using a genomics-based approach. Gene 263:211-218.
Lehrer, R. I., et al. (1991) Ultrasensitive assays for endogenous antimicrobial polypeptides. J. Immunol. Methods 137:167-173.
Lehrer, R. I. & Ganz, T. (1999) Antimicrobial peptides in mammalian and insect host defence. Curr. Opin. Immunol. 11:23-27.
Leitch; E. C. & Willcox, M. D. (1998) Synergic antistaphylococcal properties of lactoferrin and lysozyme. J. Med. Microbiol. 47:837-842.
Lim, D. J., et al. (2001) Cell biology of tubotympanum in relation to pathogenesis of otitis media—a review. Vaccine 19(Suppl 1): S17-S25.
Miyasaki, K. T., et al. (1990) In Vitro Sensitivity of Oral, Gram-Negative, Facultative Bacteria to the Bactericidal Activity of Human Neutrophil Defensins. Infect. Immun. 58(12):3934-3940.
Muhle, S. A. & Tam, J. P. (2001) Design of Gram-Negative Selective Antimicrobial Peptides. Biochemistry 2001 40:5777-5785.
O'Neil, D. A., et al. (1999) Expression and Regulation of the Human β-Defensins hBD-1 and hBD-2 in Intestinal Epithelium. J. Immunol. 163:6718-6724.
Pierce, A., et al. (1997) Lactoferrin Almost Absent From Lactating Rat Mammary Gland Is Replaced by Transferrin. In Lactoferrin: Interactions and Biological Functions (Eds. Hutchens, T. W. & Lonnerdal, B.) 125-134 (Humana Press, Totowa, New Jersey).
Plaut, A. G., et al. (2001) Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease ofHaemophilus influenzae. Vaccine. 19(Suppl 1):S148-S152.
Prellner, K., et al. (1984) Pneumococcal antibodies and complement during and after periods of recurrent otitis. Int. J. Pediatr. Otorhinolaryngol. 7:39-49.
Qiu, J., et al. (1998) Human milk lactoferrin inactivates two putative colonization factors expressed byHaemophilus influenzae. PNAS 95:12641-12646.
Schroder, J. M. & Harder, J. (1999) Human beta-defensin-2. Int. J. Biochem. Cell Biol. 31:645-51.
Selsted et al. (1993) The Journal of Biological Chemistry 268(9): 6641-6648.
Shimoda, M., et al. (1995) Morphology of Defensin-TreatedStaphylococcus aureus. Infect. Immun. 63(8):2886-2891.
Singh, P. K., et al. (1998) Production of β-defensins by human airway epithelia. PNAS 95:14961-14966.
Singh P. K., et al. (2000) Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am. J. Physiol. Lung Cell Mol. Physiol. 279: L799-L805.
Takemura, H., et al. (1996) Evaluation of Susceptibility of Gram-Positive and -Negative Bacteria to Human Defensins by Using Radial Diffusion Assay. Antimicrob. Agents Chemother. 40(10):2280-2284.
Tam, J. P., et al. (2000) Marked Increase in Membranolytic Selectivity of Novel Cyclic Tachyplesins Constrained with an Antiparallel Two-β Strand Cystine Knot Framework. Biochem. Biophys. Res. Commun. 267(3):783-790.
Yu, Q., et al. (2000) Engineered Salt-insensitive α-defensins with End-to-end Circularized Structures. J. Biol. Chem. 275(6):3943-3949.
Andalibi Ali
Ganz Tomas
Lee Haa-Yung
Li Jian-Dong
Lim David J.
Delacroix-Muirheid C.
Henley III Raymond
House Ear Institute
Knobbe Martens Olson & Bear LLP
LandOfFree
Use of antimicrobial proteins and peptides for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antimicrobial proteins and peptides for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antimicrobial proteins and peptides for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3709471